Barclays Trims Teladoc Health (NYSE:TDOC) Target Price to $20.00

Teladoc Health (NYSE:TDOC) had its price objective decreased by Barclays from $25.00 to $20.00 in a research note issued to investors on Friday, Benzinga reports. Barclays currently has an overweight rating on the health services provider’s stock.

Several other equities research analysts have also recently commented on TDOC. SVB Leerink assumed coverage on Teladoc Health in a research note on Monday, February 26th. They set a market perform rating and a $17.00 target price for the company. Canaccord Genuity Group reduced their price objective on Teladoc Health from $28.00 to $25.00 and set a buy rating for the company in a research note on Friday. Citigroup reduced their price objective on Teladoc Health from $21.00 to $19.00 and set a neutral rating for the company in a research note on Wednesday, February 21st. Royal Bank of Canada reduced their price objective on Teladoc Health from $30.00 to $25.00 and set an outperform rating for the company in a research note on Wednesday, February 21st. Finally, Cantor Fitzgerald assumed coverage on Teladoc Health in a research note on Thursday, February 29th. They issued an overweight rating and a $22.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Teladoc Health has an average rating of Hold and a consensus target price of $19.00.

Teladoc Health Trading Down 2.4 %

NYSE TDOC opened at $13.01 on Friday. The business has a 50 day simple moving average of $14.85 and a 200 day simple moving average of $17.71. Teladoc Health has a one year low of $12.65 and a one year high of $30.41. The stock has a market capitalization of $2.20 billion, a P/E ratio of -9.23 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47.

Teladoc Health (NYSE:TDOC) last released its earnings results on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The business had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. During the same period in the prior year, the business earned ($0.37) EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. Research analysts expect that Teladoc Health will post -1.06 earnings per share for the current year.

Insider Activity

In other news, insider Laizer Kornwasser sold 7,882 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the transaction, the insider now owns 57,223 shares in the company, valued at $1,097,537.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jason N. Gorevic sold 53,755 shares of Teladoc Health stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $780,522.60. Following the sale, the chief executive officer now directly owns 653,073 shares in the company, valued at $9,482,619.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the sale, the insider now owns 57,223 shares in the company, valued at $1,097,537.14. The disclosure for this sale can be found here. Insiders have sold 135,441 shares of company stock worth $2,038,251 over the last 90 days. 1.63% of the stock is currently owned by corporate insiders.

Institutional Trading of Teladoc Health

A number of hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in Teladoc Health by 14.6% during the fourth quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock worth $87,000 after acquiring an additional 515 shares during the period. M&T Bank Corp increased its position in Teladoc Health by 5.5% in the fourth quarter. M&T Bank Corp now owns 11,152 shares of the health services provider’s stock worth $241,000 after buying an additional 584 shares during the last quarter. Van ECK Associates Corp increased its position in Teladoc Health by 20.3% in the fourth quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock worth $77,000 after buying an additional 606 shares during the last quarter. Arizona State Retirement System increased its position in Teladoc Health by 1.4% in the third quarter. Arizona State Retirement System now owns 46,602 shares of the health services provider’s stock worth $866,000 after buying an additional 650 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in Teladoc Health by 4.3% in the third quarter. Victory Capital Management Inc. now owns 17,946 shares of the health services provider’s stock worth $334,000 after buying an additional 748 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.